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ABSTRACT
The COVID-19 outbreak has become a global emer-
gency since December 2019. Analysis of SARS-
CoV-2 sequences can uncover single nucleotide
variants (SNVs) and corresponding evolution pat-
terns. The Global Evaluation of SARS-CoV-2/hCoV-
19 Sequences (GESS, https://wan-bioinfo.shinyapps.
io/GESS/) is a resource to provide comprehensive
analysis results based on tens of thousands of
high-coverage and high-quality SARS-CoV-2 com-
plete genomes. The database allows user to browse,
search and download SNVs at any individual or
multiple SARS-CoV-2 genomic positions, or within
a chosen genomic region or protein, or in certain
country/area of interest. GESS reveals geographical
distributions of SNVs around the world and across
the states of USA, while exhibiting time-dependent
patterns for SNV occurrences which reflect develop-
ment of SARS-CoV-2 genomes. For each month, the
top 100 SNVs that were firstly identified world-widely
can be retrieved. GESS also explores SNVs occurring
simultaneously with specific SNVs of user’s inter-
ests. Furthermore, the database can be of great help
to calibrate mutation rates and identify conserved
genome regions. Taken together, GESS is a powerful
resource and tool to monitor SARS-CoV-2 migration
and evolution according to featured genomic varia-
tions. It provides potential directive information for
prevalence prediction, related public health policy
making, and vaccine designs.
INTRODUCTION
As early as December 2019, several cases of human Coron-
avirus Disease 2019 (COVID-19) were reported in Wuhan,
Hubei province in China. This is the seventh global out-
break of coronavirus utmost severe type in human and was
caused by a novel coronavirus, the Severe Acute Respiratory
Syndrome Coronavirus 2 (SARS-CoV-2) (1). Up to date
of 22 July 2020, the pandemic of SARS-CoV-2 has caused
over 13.3 million confirmed infection, including nearly 578
000 deaths all over the world. Since early 2020, abundant
of efforts have been invested to SARS-CoV-2 related stud-
ies. Even though there were very limited SARS-CoV-2 com-
plete genome data, many individual studies reported that
the virus had gradually accumulated genomic sequence al-
terations, which were commonly seen in different widely
spread viral strains. Particularly, single-nucleotide variants
(SNVs) and other types of mutations were found in diverse
countries/areas and across multiple time points (2,3) within
the 29 903-nucleotide (nt) SARS-CoV-2 complete genome.
The SNVs might have potential influence on the viral in-
fectivity, or affect the biological functions, or shape pro-
tein structures, such as A23403G causing an AA change
on Spike protein: D614G, and mutations on the viral Nsp6
and ORF10 (4–6). Now more than 66 000 viral genomic
sequences of hCoV-19 have been submitted and shared via
the online platform, the Global Initiative on Sharing Avian
Influenza Data (GISAID) (https://www.gisaid.org/) as of
July 2020 (7,8). The availability of most updated genome
sequences brings us opportunities to discover newly emerg-
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ing viral mutations that significantly contributing to SARS-
CoV-2 transmission. Hence, an advanced systematic inves-
tigation of global SARS-CoV-2 mutations is needed to un-
cover the relationship between genomic features and geo-
graphical locations over the time of outbreak. Moreover,
the study of co-occurrence correlations among the muta-
tions will provide a better understanding of how mutations
orchestrate the spreading and evolution of SARS-CoV-2 at
genomic level.
So far several databases have been published with focus
on mutations of SARS-CoV-2 and their relative functions,
such as SARS-CoV-2 project of ViPR (9) and the GISAID
(7,8). The ViPR is a virus pathogen platform which pro-
vides options of searching and downloading mutation in-
formation of SARS-CoV-2. As analytic tools for sequence
alignment and visualization, it lacks enough analytical re-
sults connecting sequence mutations with countries/areas
and associated timelines of occurrence, which are critical
to explore the potential transmission paths of SARS-CoV-
2. The GISAID also features data searching, downloading
and related tools integrated with an online app Next hCoV-
19 based on Nextstrain (10), which yields both the phyloge-
netic analysis and geographical information of the SARS-
CoV-2 samples. However, as a Flu and SARS-CoV2 ge-
nomic database, the GISAID is dedicated on viral clades,
which were determined based on several current genetic
marker variants, instead of systematic analysis on all indi-
vidual mutations. Given no clues whether new viral clades
would create during most recent viral evolution, we must
monitor all possible viral sequence variants over the time
and pay more attentions to newly emerging mutations.
Here we present the Global Evaluation of SARS-CoV-
2/hCoV-19 Sequences (GESS), a database developed based
on SNVs identified among over forty-two thousand high-
quality and high-coverage SARS-CoV-2 complete genome
sequences as of July 22nd, 2020. There will be more and
more SARS-CoV-2 sequences collected by GESS with
weekly updates. We do not include phylogenetic analysis in
GESS, considering that many arguments have been raised
about current phylogenetic network analysis due to unbal-
anced numbers of virus samples collected around the world
that led to biased sampling (11). Particularly very few viral
genomes during the early breakout of COVID-19 in Wuhan
were available which makes the analysis more challenging.
Also, lack of strong evidences on homologous recombina-
tion and horizontal gene transfer brought more questions
about the results of phylogenetic network at this moment
(12). Instead, the purpose of GESS is to provide multi-
ple embedded functions and mutation results for users to
quickly elucidate detailed information for SNVs without re-
analyzing tens of thousands of whole genome sequences.
This assists researchers who have no background or capac-
ity for sequence analysis to find SNVs of their own inter-
est, besides those mutation hotspots which have been pub-
lished and discussed. The novel functions by the GESS can
give users opportunities to study SARS-CoV-2 mutations
from different angles. In general, GESS features several lev-
els of evaluations on all SNVs. First, it allows user to achieve
and download the SNV information, including amino acid
(AA) changes caused by the SNVs on viral genes, through
different options by either searching single or multiple vi-
ral genome positions, or selecting a specific genomic region
or protein, or focusing on samples collected from a certain
country/area. GESS features interactive maps of geograph-
ical distributions of selected SNVs, both worldwide and in
the states of USA, in addition to the time-dependent pat-
terns of SNV occurrence ratios. Moreover, the ‘genome re-
gion search’ on specific genomic location or protein has ap-
plications for downstream study, including assisting people
on vaccine designs by examining the evolutionary conser-
vation of viral sequences. Interestingly, many SNVs were si-
multaneously identified on the same genomes (13–15), sug-
gesting co-occurrence or cooperation between those viral
sequence variants. Hence, GESS highlights one function,
‘concurrence search’, to identify all SNVs that show sig-
nificant concurrence ratios with specified SNV chosen by
user. This may help elucidate how SARS-CoV-2 utilizes the
sequence mutations to orchestrate its affiliation with po-
tential receptors, while exploring specific viral strains in
fewer population or within special geographical locations.
Such results are also very useful for epistasis research in
SARS-CoV-2. Another GESS function of ‘SNV birth query’
is a necessity to monitor SNVs newly detected in each
month, which is important to uncover their original coun-
tries or areas and help virus prevention as well as poten-
tial treatments. Combining all these functions, GESS gives
users comprehensive overviews and detailed information of
SARS-CoV-2 SNVs, with distinct transmission at different
countries/areas and evolution patterns over time.
MATERIALS AND METHODS
Data collection
The first version of GESS database contains 42 461 high-
quality and high-coverage SARS-CoV-2/hCoV-19 genome
sequences downloaded from GISAID as of 22 July 2020.
Total 12 252 genomic locations were detected with SNVs by
sequence alignments against the reference genome, Wuhan-
Hu-1 (NCBI: NC 045512.2). Wuhan-Hu-1 genome is the
full-length genome sequence of the SARS-CoV-2 detected
in China in December 2019 (16). It has been collected
in the NCBI GenBank as reference. To our knowledge,
over hundreds SARS-CoV-2 genetic and genomic studies
used Wuhan-Hu-1 as the reference genome (17,18). Many
main vaccines, such as MRNA mRNA-1273 (19), BNTX
BNT162b2 (20) and Ad5-nCoV (21,22) vaccines, were de-
signed based on Wuhan-Hu-1 sequence as well. Another
hCoV-19 genome, Wuhan-WIV04 (23), was identified in
China in December 2019 as well, which has been used as
the reference by GISAID and other studies. These two
genomes, Wuhan-WIV04 and Wuhan-Hu1, are almost ex-
actly the same, except that Wuhan-Hu-1 has 12 more poly-
As at the end of the viral genome.
All results of SARS-CoV-2 single nucleotide mutation
will be updated weekly and downloaded from GESS with
technical support by GISAID.
Database structure
The GESS database is built using R language with Shiny
package, whose infrastructure is shown in Figure 1A. The
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Figure 1. Overview of GESS database. (A) The infrastructure of GESS database. The central part is individual SNV analysis and concurrence of SNVs.
(B) Home page of GESS database. Besides a brief description of the website, the ‘Home’ page includes distributions of viral genome numbers around the
world, or in the USA, or within each month. Several subpages contain different functions under the ‘Home’ page, in addition to the ‘Tutorial’ with the
introduction to the use of GESS.
from the GISAID database and processed as in the pa-
per (14). After filtering low-quality or low-coverage sam-
ples and removing white spaces within the sequences, we
used a software, minimap2 (24), to pairwise align SARS-
CoV-2 sequences with the reference genome Wuhan-Hu-1.
Minimap2 is a fast and efficient pairwise aligner that can
also handle alignment of long sequences in the fasta format.
The results of pairwise alignment will not be affected by
other sequences, which can avoid the interference caused by
newly collected genome samples. Then a tool ANNOVAR
(25) was adopted to annotate variants based on NCBI ref-
erence sequence: NC 045512.2. SNVs were identified and
matched with corresponding sample information, including
patients’ geographical locations and dates of sample collec-
tions, among others. In order to examine whether two SNVs
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SNVs is calculated in the way,
R (A, B) = |A∩ B|
min (|A| , |B|) ,
where A and B are any two SNVs detected from at least 0.1%
of total viral genomes in the study, |A∩ B| is the number
of samples presenting both A and B, whereas min(|A|, |B|)
represents the minimum number of samples bearing either
A or B. The larger the concurrence ratio, the more likely two
SNVs coexist in the same viral genomes.
For any selected SNVs, GESS first shows their AA anno-
tations, followed by interactive maps of SNVs’ distributions
around the world and USA. The patterns of time-dependent
occurrence ratios of SNVs reveal their frequencies in the
populations for each month, suggesting the roles of SNVs
during viral transmission and evolution. Indeed, all infor-
mation involved in the result webpages can be downloaded
directly from the website for further research and future
publication.
RESULTS
The user interface of GESS database starts with a ‘Home’
page showing a brief summary of the number of high-
quality and high-coverage samples collected from the world
and the USA, separately (Figure 1B). The ‘SNV results
download’ provides detailed information updated weekly
for all SNVs. The profile up to 22 July 2020 can be found
in Supplemental materials with this paper. GESS consists
a set of ‘Search Functions’ pages, ‘Tutorial’, ‘Acknowledge-
ment’, and information of the ‘Research Team’ (Figure 1B).
Five search options are provided on separate sub-pages of
GESS: SARS-CoV-2 ‘Genome position search’, ‘Genome re-
gion search’, ‘Country/Area search’, ‘Concurrence search’
and ‘SNV birth query’. The central part of all searches (Fig-
ure 1A) includes features of individual SNVs including cor-
responding sample information and concurrence correla-
tions with each other. Here we present details of each search
function provided by current version of GESS.
Genome position search
The page of ‘Genome position search’ contains two subset
options: ‘Single position’ and ‘Multiple positions’ search.
The ‘Single position’ search allows user to load only one
SARS-CoV-2 genomic site at the select box. There are likely
multiple different SNVs at the same genomic site. The select
gear grants user to choose any SNVs of interest with cor-
responding mutation annotations. ‘All’ and ‘None’ buttons
enables selection of all or none of SNVs at the input po-
sition for convenience. In ‘Multiple positions’ search, users
can enter or select multiple genome positions in the selec-
tion box. Then the dropdown selection box shows SNVs at
the input positions to let user select their interests. The rela-
tionship between selected SNVs can be determined as either
‘AND’ or ‘OR’ by ‘Relationship’ radio buttons. The ‘AND’
option reveals the viral genomes carrying all selected SNVs
simultaneously, whereas the ‘OR’ option leads to samples
with any one of SNVs chosen. The consequent results are
exhibited in the tabs of ‘World-Wide Status’, ‘United States
Status’ and ‘Time Series’ with statistics on input SNVs. The
interactive maps in both ‘World-Wide Status’ and ‘United
States Status’ allow user to get more detailed information
on the countries/areas or the states of the USA by mov-
ing the mouse on the maps to any part of their specific in-
terest. Additionally, a table within the ‘World-Wide Status’
tab can be downloaded showing the counts of SNVs in each
country/area. By clicking specific country/area, user can
get SNV distributions in different divisions or locations of
selected country/area. The ‘Time Series’ tab displays bar
plots of SNVs frequencies, indicating the temporal ratio of
genomes bearing the mutations in each month.
Genome region search
The ‘Genome region search’ allows user to explore SNVs in
a special region of the viral genome (‘Region based search’)
or on a specific protein (‘Protein based search’). User has
an additional option to filter rare SNVs by choosing the
count cut-off in the box. SNVs within selected region or
protein are presented in the dot plot, where y-axis repre-
sents numbers of samples bearing the SNVs while nts and
AAs are listed on corresponding genomic positions. The
plot can be downloaded by clicking the button ‘camera’.
Users are encouraged to check any individual SNV by mov-
ing the mouse. The detailed information for selected SNV
is presented after being automatically redirected to the re-
sults in the page of ‘Genome position search’ by clicking
it. For example, on spike protein (S), A23403G shows the
highest incidence on 32 915 samples, leading to an AA
change on the S:D614G, which was regarded as a viral
strain with high infectivity (26). This mutation was found
mostly in England and USA, followed by almost all other
countries/areas in the world (Figure 2A and B). The pre-
vailing ratios of A23403G increased from 2.51% in January
2020 up to 96.52% in June and 99.23% in July 2020 (Figure
2C), indicating a dominant role of this mutation in driving
the evolution and spreading of SARS-CoV-2 (13).
Country/area search
The function of ‘Country/Area search’ helps user to fo-
cus on SNVs identified in a certain country or area. The
summary of SNVs in the country/area includes names of
SNVs, genomic positions and annotations, numbers and
percentages of viral genomes carrying the SNV in selected
country/area. User can also filter or do a quick search on
SNVs given interesting attributes by adding the key word in
the search box. The summary table can be downloaded by
user as either CSV format or Excel format. With curiosity
of learning more details about any specific SNV, user may
click on the SNV and then will be directed to the results on
the webpage of ‘Genome position search’.
Concurrence search
Among over forty thousand SARS-CoV-2 genomes, SNVs
were observed on approximately 29% of genome positions.
Some SNVs are considered as random mutations, which
might have no biological significance on viral infection, mi-
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Figure 2. An example to show the process of data mining via GESS. (A) World map of distribution of the mutation A23403G (S:D614G). (B) Table
including event counts of A23403G in different counties/areas. (C) Temporal occurrence ratios of A23403G along the time. (D) SNVs in concurrence with
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Figure 3. Function of ‘SNV birth query’. (A) Word cloud of new SNVs in March 2020. (B) Table listing corresponding information for new SNVs in March
2020. (C) Word cloud of new SNVs and (D) information of new SNVs in June 2020.
be important drivers of virus genetic diversity in popu-
lations. It has already been noticed that some of SARS-
CoV-2 SNVs were detected in the same patients simultane-
ously, suggesting potential functional interplay and cooper-
ation among the mutations on these genomic sites. The con-
currence ratio (see Methods) was calculated for each pair
of SNVs that were identified in at least 0.1% of all viral
genomes. The webpage of ‘Concurrence search’ allows user
to choose any one of SNVs from the full list. After click-
ing the search button, user may browse, search, and sort
all other SNVs with the information about SNV annota-
tions, counts, and concurrence ratios. The filter options un-
der each column can help user concentrate on SNVs of their
interests. The tables containing all details about the SNV
results can be downloaded from GESS. Take A23403G as
an example here, we identified 13 other SNVs in at least
1000 viral genomes which had concurrence ratios larger
than 0.9 with A23403G (Figure 3D). These co-occurrent
SNVs with A23403G includes nonsynonymous mutations
C14408T leading to an AA change on ORF1ab (Genbank,
2020) (13), G28881A, G28882A, and G28883C on ORF9
(Genbank, 2020) among others. Another interesting non-
synonymous mutation is G10097A on ORF1a/1ab, which
was detected first time in March 2020 mainly from the vi-
ral genomes of England and Scotland collected in the study.
These SNVs also showed a similar trend of increased inci-
dences together with A23403G.
SNV birth query
Similar to other viruses, SARS-CoV-2 have created genetic
diversity via temporally accumulated mutations. In order to
uncover the connections between featured mutations and
viral migrations at a specific time point, ‘SNV birth query’
is set up for users to overview new SNVs which were discov-
ered for the first time in each month. After the time selected,
a word cloud plot is popped out with at most top 100 SNVs
which had highest occurrence ratios in selected month (Fig-
ure 3A). The larger size of the SNV in the word cloud, the
higher frequency of the SNV. More detailed information for
all newly emerging SNVs is provided in the table on the
webpage. In addition to SNVs, their counts, and percent-
age of samples with the SNVs in total genomes collected in
the month of query, the table lists the country/area which
had the most number of corresponding SNVs, and other
information in the top country/area during the same time
period, e.g. numbers of the genomes with the SNVs, num-
bers of total samples, and their ratios in percentages (Fig-
ure 3B). The table can be downloaded from the webpage in
either excel or csv format. When clicking the SNV in the
word cloud plot or in the table, user is automatically redi-
rected to the page of ‘Genome position search’ with details
about the SNV. For example, the mutation of C27046T had
the highest incident number 469 (2.67% of all samples) that
was identified for the first time in March 2020 (Figure 3A).
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Figure 4. Examples to use GESS to calibrate sequence conservation for vaccine design. (A) Helper T lymphocyte-based epitope LLLQYGSFCTQLNRA
on the genomic region: 23 816 – 23 860 (Spike). The y-axis in the dot plot represents the numbers (base-10 log scale) of viral genomes with point mutations
at each position. Nucleotides and amino acids are marked, respectively, under the dot plot at corresponding genomic locations. (B) B lymphocyte epitope,
QGEIKDATPSDF, within the viral genome: 25 441 – 25 476 (ORF3a). The screenshots were taken from GESS.
in Netherlands in March, where 100 out of 589 (∼16.98%)
viral genomes bore this new SNV (Figure 3B). Several other
European countries, e.g. England, Iceland, and Sweden, fol-
lowed Netherlands in terms of numbers of genomes identi-
fied to carry C27046T, suggesting that the mutation spread
quickly in March, or the mutation had already existed be-
fore March but was not discovered from our database due to
limited numbers of samples or biased sampling at the early
stage of COVID-19 breakout. As comparison, we checked
the GESS with more recent dates. There were 569 newly
emerging SNVs (Figure 3C) uncovered in June 2020, ma-
jority of which were specific to one country/area only (Fig-
ure 3D). For example, all 58 genomes carrying A2292C
in June were from India, which led the AA mutation on
ORF1a:Q676P or Nsp2:Q496P. Another nonsynonymous
SNV, G2036T, causing alteration on ORF1ab:A591S, or
ORF1a:A591S, or Nsp2:A411S, was found only in USA in
June (Figure 3D).
DISCUSSION
Comparing to existing databases of SARS-CoV-2 muta-
tions, GESS provides a more convenient and straightfor-
ward way to obtain the comprehensive overview on SARS-
CoV-2 SNVs by easy operations. The summary pages of
GESS contain the information about numbers of samples
collected by date around the world and in the USA, with
details for each month. Multiple search functions on GESS
offer users a larger flexibility to browse and search SNV pat-
terns from different aspects, while keeping the focus on SNV
characteristic. Notably, one important feature of GESS is
usage of correlation function on SNVs, where a parame-
ter, concurrence ratio R, is adopted to identify SNVs cooc-
curred simultaneously. GESS also provides a novel func-
tion for SNV birth query to assist monitoring newly oc-
curred SNVs each month. This may help user to better un-
derstand the migration, transmission, spread and evolution
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One of most important ways to combat viral pandemic is
to develop effective vaccines. Much effort has been devoted
to design vaccines against SARS-CoV2 globally. Until now,
there are more than 100 planned and ongoing clinical stud-
ies of vaccines for COVID-19, several of which have entered
Phase II or III clinical trial. Ideal vaccine must have strong
immunogenicity with useful T lymphocyte or B lymphocyte
response via their specific epitopes, and less immunotox-
icity. For this purpose, several groups designed and opti-
mized different HLA-based cytotoxic T-lymphocyte, helper
T-lymphocyte and B-lymphocyte epitopes, and linked the
selected epitopes together and clonal to expression vectors
(28–31). In order to produce a universal antibody to neu-
tralize different viral strains, we must also consider the con-
servation of targeted sequences. The database of GESS can
be of great help to calibrate mutation rates for specially de-
signed regions. For example, Helper T lymphocyte-based
epitope LLLQYGSFCTQLNRA is located on the Spike
protein within the genomic region: 23 816 – 23 860 (30). Us-
ing ‘Genome Region Search’, we found that the sequences
within 23 816 – 23 848 were very conserved (Figure 4A),
where very few mutation events occurred among over forty
thousand viral genomes. However, about twenty samples
bore mutations on the genomic positions 23 849, 23 854 and
23 856, suggesting possible limitations of this vaccine design
due to mutations on these sites. Another example is B lym-
phocyte epitope located on ORF3a, QGEIKDATPSDF,
within the viral genome: 25 441 – 25 476 (28), where the mu-
tation levels seemed higher than those of previous design on
Spike protein, indicating potential restrictions or reduced
effectiveness of the vaccine for those mutated viruses.
The example results from GESS presented in the pa-
per was based on metadata provided by GISAID as of
22 July 2020. The subsequent updates will be performed
weekly given newly submitted and collected whole genome
sequencing data passing the quality control. The goal of
GESS is to provide a user-friendly, state-of-art database to
explore the associations and interactions between SNVs.
In general, by fetching the data of SNVs and using func-
tions embedded in GESS to analyze their significant fea-
tures, users may gain new insights into the molecular drivers
of SARS-CoV-2 transmission, migration, and evolution.
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